The purpose of this randomized controlled trial was to determine if weekly testosterone administration, beginning 2 weeks before surgery and ending 6 weeks after surgery, could effectively prevent short-term catabolic loss of lean mass in patients undergoing ACL reconstruction and structured rehabilitation. It was hypothesized that testosterone would increase lean mass and leg strength and improve clinical outcome scores relative to placebo. The 5 studies showed heterogeneity in patient populations, procedure type, dosage, duration, testosterone therapy protocol, clinical outcomes, and follow-up duration. This increase in lean mass was found to persist after the return of serum testosterone levels to baseline. Patients receiving an 8-week course of 200 mg/wk of testosterone cypionate were found to have a greater increase in lean mass at 6 weeks after ACL reconstruction compared to patients administered placebo. However, because safety was not a primary or secondary outcome of this study, future studies specifically investigating the safety of testosterone administration in patients undergoing ACL surgery are necessary to conclusively determine the safety of perioperative testosterone supplementation in this population.
All patients who were assigned to a treatment were included in statistical analyses, except for 1 participant who was dropped from the study because he did not undergo his scheduled ACL surgery. The TAS has been validated for assessing clinical outcomes in the setting of knee surgery, with high test-retest reliability in this setting.11,31 The TAS is scored from 1 to 10, with 0 representing disability and 10 signifying participation in a professional sport. The testosterone group received a 200-mg dose of intramuscular testosterone cypionate weekly for 8 weeks beginning 2 weeks before surgery. This study also assessed short-term changes in dynamic muscle strength and patient-reported outcome measures. Supraphysiological testosterone supplementation may be a useful adjunct therapy for counteracting muscle atrophy after ACL reconstruction. There were no significant between-group differences in injured leg strength or clinical outcome scores. Secondary outcomes were extensor muscle strength, Tegner activity score, and Knee injury and Osteoarthritis Outcome Score.
All 4 studies showed significant improvements in functional independence, BMD, muscle volume in the operative and nonoperative leg, Harris hip score, gait speed, Katz score, lean body mass, and strength. Prior studies of perioperative testosterone supplementation have used 600 mg/wk of testosterone enanthate for 4 weeks and 600 mg/wk for 10 weeks.2,7 The goal in dosing was to elevate testosterone levels in the testosterone group to approximately 1000 to 1200 ng/dL; however, serum levels reached a peak mean value of 860 ng/dL. This may in part be because of the baseline difference in injured leg strength between the 2 study groups, which approached significance. Line plot of the change in peak extension torque of the injured leg from baseline to 1 day before surgery and 6, 12, and 24 weeks after surgery. Effect of testosterone on the change in strength of the injured leg from baseline. Line plot of the change in peak extension torque of the uninjured leg from baseline to 1 day before surgery and 6, 12, and 24 weeks after surgery.
After age 35, bone breakdown happens faster than your body can replace it. Up until about age 30, your body naturally builds more bone than you lose. Osteoporosis happens as you age and your bones lose their ability to regrow and reform themselves. But this can be a sign that you should visit a healthcare provider for a bone density test. You might not know you have osteoporosis until it causes you to break a bone. If you have osteoporosis, your bones are much more fragile than they should be, and are much weaker.
Although the present study was sufficiently powered for the outcome of lean mass, the small sample size and wide age range of patients selected may have contributed to a failure to document differences in baseline leg strength and other factors affecting clinical outcomes. Prior research has suggested that perioperative supraphysiological testosterone supplementation may improve clinical outcomes, including rehabilitation milestones such as early standing after knee replacement surgery.2 The present study also did not find a significant difference in postoperative strength of the injured leg between the testosterone and placebo groups. Our results suggest that testosterone therapy may be useful as an adjunct to postoperative physical therapy in eugonadal patients by causing an increase in lean mass that persists for an extended period without residual disturbance of baseline serum testosterone levels. Nonetheless, the trauma of surgical repair and postoperative mobility limitations can exacerbate the loss of muscle mass and strength, which may prolong the already arduous rehabilitation process and potentially impair long-term outcomes.3,24 One study reported that 60% of patients undergoing ACL reconstruction did not return to preinjury activity levels within 2 years.17
As more individuals begin to age into joint replacements, it is probable that orthopedic surgeons will treat these patients, underscoring the need to elucidate the effects of the long-term use of TRT . This study sought to examine outcomes of reverse total shoulder arthroplasty (RSA) in patients receiving TRT. To evaluate the effect of testosterone supplementation during the perioperative period on outcomes following orthopedic surgery. In the field of orthopaedic surgery, research is beginning to delineate the complex relationship between TRT and the development of orthopaedic conditions and potential effects on surgical interventions and outcomes.
Furthermore, since the goal of this study was to only investigate the reverse form of TSA, the CPT code for TSA was not used. Contrarily, Amory et al. (2003) conducted a controlled trial, where the treatment group received a testosterone intramuscular injection four times over a 3-week period prior to total knee arthroplasty . The results of the present study demonstrated that rates of revision were similar between the TRT group (12.0%) and control group (11.0%). While the subscapularis is not universally repaired following RSA , the surgeons who do decide to repair it may need to pay closer attention to the negative impacts that TRT could have on tendon integrity. On the other hand, it has been demonstrated that testosterone could impair tissue remodeling of tendons due to the downregulation of matrix metallopeptidase .

Gender: Female

Social links